A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business description not available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 4.1B | 4.1B | 2.6B | 18.5B | 17.6B | 16.1B |
| Net Income | 330M | 330M | 443M | 3.9B | 3.7B | 3.2B |
| EPS | $0.72 | $0.72 | $1.59 | $13.89 | $13.25 | $11.51 |
| Free Cash Flow | 736M | 736M | 334M | 1.3B | 3.5B | 4.1B |
| ROIC | 3.4% | 3.0% | 15.5% | 41.5% | 17.2% | 18.9% |
| Gross Margin | 47.2% | 47.2% | 54.3% | 54.6% | 57.7% | 56.0% |
| Debt/Equity | 0.00 | 0.23 | 0.47 | 3.55 | 0.56 | 0.45 |
| Dividends/Share | $0.59 | $0.59 | $1.50 | $5.79 | $6.23 | $6.07 |
| Operating Income | 541M | 541M | 579M | 4.8B | 4.7B | 4.2B |
| Operating Margin | 13.1% | 13.1% | 22.2% | 26.0% | 26.8% | 26.1% |
| ROE | 2.8% | 2.8% | 21.2% | 192.6% | 25.8% | 25.1% |
| Shares Outstanding | 456M | 456M | 277M | 277M | 278M | 281M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 16.1B | 16.1B | 17.6B | 18.5B | 2.6B | 4.1B | 4.1B |
| Gross Margin | 55.3% | 56.0% | 57.7% | 54.6% | 54.3% | 47.2% | 47.2% |
| R&D | -2.2B | -2.2B | -2.4B | -2.1B | -294M | -446M | -446M |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | 4.5B | 4.2B | 4.7B | 4.8B | 579M | 541M | 541M |
| Op. Margin | 28.1% | 26.1% | 26.8% | 26.0% | 22.2% | 13.1% | 13.1% |
| Net Income | 3.5B | 3.2B | 3.7B | 3.9B | 443M | 330M | 330M |
| Net Margin | 21.9% | 20.2% | 21.0% | 21.0% | 17.0% | 8.0% | 8.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | 21.0% | 18.9% | 17.2% | 41.5% | 15.5% | 3.0% | 3.4% |
| ROE | 27.5% | 25.1% | 25.8% | 192.6% | 21.2% | 2.8% | 2.8% |
| ROA | 15.4% | 14.0% | 12.7% | 13.2% | 10.7% | 2.0% | 2.0% |
| Cash Flow | |||||||
| Op. Cash Flow | 3.6B | 5.0B | 4.8B | 4.2B | 605M | 1.1B | 1.1B |
| Free Cash Flow | 2.6B | 4.1B | 3.5B | 1.3B | 334M | 736M | 736M |
| Owner Earnings | 3.6B | 5.0B | 4.8B | 4.2B | 605M | 1.1B | 1.1B |
| CapEx | 965M | 912M | 1.3B | 2.9B | 270M | 366M | 366M |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | 366M |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | 27.0% | 18.2% | 26.4% | 68.9% | 44.7% | 33.2% | 33.2% |
| Capital Allocation | |||||||
| Dividends Paid | 1.6B | 1.7B | 1.7B | 1.6B | 416M | 270M | 270M |
| Dividend Yield | 1.7% | 1.5% | 1.2% | 1.3% | 0.4% | 0.1% | 0.2% |
| Share Buybacks | 2.2B | 1.7B | 1.8B | 526M | 0 | 0 | 0 |
| Buyback Yield | 2.2% | 1.4% | 1.1% | 0.5% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 1.2B | 498M | 1.5B | 1.7B | 363M | 583M | 583M |
| Balance Sheet | |||||||
| Net Debt | 3.9B | 4.4B | 7.0B | 7.0B | 827M | 2.4B | -303M |
| Cash & Equiv. | 796M | 1.4B | 1.1B | 147M | 163M | 303M | 303M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.37 | 0.45 | 0.56 | 3.55 | 0.47 | 0.23 | 0.00 |
| Interest Coverage | 11.6 | 23.9 | 15.8 | 8.6 | 12.0 | 4.7 | 4.7 |
| Equity | 12.8B | 12.9B | 14.4B | 2.0B | 2.1B | 11.9B | 11.9B |
| Total Assets | 22.9B | 23.1B | 29.2B | 29.5B | 4.1B | 16.4B | 16.4B |
| Total Liabilities | 10.0B | 10.7B | 14.8B | 14.5B | 2.0B | 4.5B | 4.5B |
| Intangibles | 0 | 1.3B | 1.8B | 2.2B | 288M | 11.0B | 11.0B |
| Retained Earnings | 12.1B | 12.2B | 13.3B | 12.6B | 15.0B | 0 | 0 |
| Working Capital | 2.6B | 2.6B | 2.5B | 2.4B | 322M | 223M | 223M |
| Current Assets | 7.9B | 7.6B | 9.2B | 9.7B | 1.4B | 2.0B | 2.0B |
| Current Liabilities | 5.3B | 4.9B | 6.7B | 7.3B | 1.1B | 1.8B | 1.8B |
| Per Share Data | |||||||
| EPS | 12.32 | 11.51 | 13.25 | 13.89 | 1.59 | 0.72 | 0.72 |
| Owner EPS | 12.54 | 17.82 | 17.25 | 15.21 | 2.18 | 2.41 | 2.41 |
| Book Value | 45.04 | 46.01 | 51.84 | 7.26 | 7.53 | 26.03 | 26.03 |
| Cash Flow/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.72 |
| Dividends/Share | 5.65 | 6.07 | 6.23 | 5.79 | 1.50 | 0.59 | 0.59 |
| Shares Out. | 285.3M | 280.6M | 277.8M | 277.4M | 277.5M | 456.4M | 456.4M |
| Valuation | |||||||
| P/E Ratio | 29.1 | 37.4 | 44.7 | 27.2 | 258.8 | 589.5 | 528.8 |
| P/FCF | 39.1 | 29.6 | 46.6 | 79.9 | 340.5 | 264.5 | 237.3 |
| EV/EBIT | 23.5 | 29.9 | 36.3 | 23.3 | 197.9 | 364.3 | 322.2 |
| Price/Book | 8.0 | 9.4 | 11.4 | 52.1 | 54.5 | 16.4 | 14.7 |
| Price/Sales | 6.4 | 7.5 | 9.3 | 5.7 | 43.7 | 47.0 | 42.2 |
| FCF Yield | 2.6% | 3.4% | 2.1% | 1.3% | 0.3% | 0.4% | 0.4% |
| Market Cap | 102.2B | 120.9B | 164.5B | 104.9B | 113.8B | 194.8B | 174.7B |
| Avg. Price | 341.46 | 413.07 | 524.34 | 450.76 | 365.76 | 448.72 | 382.80 |
| Year-End Price | 358.36 | 430.74 | 592.07 | 378.18 | 410.28 | 426.76 | 382.80 |
Novonesis (Novozymes A/S) B passes 3 of 9 quality checks, indicating weak fundamentals.
Novonesis (Novozymes A/S) B trades at 528.8x trailing earnings, compared to its 15-year median P/E of 33.3x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 237.2x vs a median of 42.9x. The company's 5-year average ROIC is 19.2% with a gross margin of 54.0%. Total shareholder yield (dividends) is 0.2%. At current prices, the estimated annualized return to fair value is -30.4%.
Novonesis (Novozymes A/S) B (NSIS-B-CO) has a current P/E ratio of 528.8, compared to its historical median P/E of 33.3. The stock is currently considered Expensive based on its historical valuation range.
Novonesis (Novozymes A/S) B (NSIS-B-CO) has a 5-year average return on invested capital (ROIC) of 19.2%. This indicates strong capital allocation and a potential competitive advantage.
Novonesis (Novozymes A/S) B (NSIS-B-CO) has a market capitalization of $174.7B. It is classified as a large-cap stock.
Yes, Novonesis (Novozymes A/S) B (NSIS-B-CO) pays a dividend with a trailing twelve-month yield of 0.15%.
Based on historical P/E analysis, Novonesis (Novozymes A/S) B (NSIS-B-CO) appears expensive. The current P/E of 528.8 is 1490% above its historical median of 33.3. The estimated fair value CAGR (P/E method) is -35.1%.
Novonesis (Novozymes A/S) B (NSIS-B-CO) reported annual revenue of $4.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
Novonesis (Novozymes A/S) B (NSIS-B-CO) has a net profit margin of 8.0%. This is a modest margin.
Novonesis (Novozymes A/S) B (NSIS-B-CO) generated $736 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Novonesis (Novozymes A/S) B (NSIS-B-CO) has a debt-to-equity ratio of 0.23. This indicates a conservatively financed balance sheet.
Novonesis (Novozymes A/S) B (NSIS-B-CO) reported earnings per share (EPS) of $0.72 in its most recent fiscal year.
Novonesis (Novozymes A/S) B (NSIS-B-CO) has a return on equity (ROE) of 2.8%. This indicates moderate shareholder returns.
Novonesis (Novozymes A/S) B (NSIS-B-CO) has a 5-year average gross margin of 54.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for Novonesis (Novozymes A/S) B (NSIS-B-CO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Novonesis (Novozymes A/S) B (NSIS-B-CO) has a book value per share of $26.03, based on its most recent annual SEC filing.
No recent press releases.